As these associations were independent of clinical stage, and were similar for amyloid-negative CN individuals (apart from NfL which did not show differences in this group), p-tau subgroups may, in addition to disease severity, reflect biological subtypes of AD that have distinct profiles of amyloid metabolism and synaptic integrity markers, apparently already when cognition is still unimpaired. This evidence concerns the gene NEFL and Alzheimer disease.